Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2015

View Archived Issues

ARM-210 from ARMGO Pharma receives FDA orphan drug designation

Aduro's CRS-207 receives EMA orphan drug designation for malignant pleural mesothelioma

CapGenesis starts exploratory trial of topical trans-capsaicin in osteoarthritis knee pain

Monoclonal antibody combination ASN-100 enters clinical study for S. aureus infection

Presage Biosciences inlicenses voruciclib

Adaptimmune initiates phase I/II study of NY-ESO TCR therapy in NSCLC

FDA grants orphan drug designation to PhaseBio's vasomera

Ubenimex receives FDA orphan drug designation for the treatment of PAH

Debiotech and ARTORG announce collaboration to develop next-generation artificial pancreas

Allergan and Rugen Therapeutics to develop drugs to treat autism spectrum disorders and OCD

Axsome Therapeutics closes initial public offering

New phase I trial investigates panitumumab-IRDye800 as an optical imaging agent

New bispecific antibody prodrug shows preclinical efficacy

Taiho presents preclinical data for NEDD8-activating enzyme inhibitor TAS-4464

Aurigene Discovery reports preclinical data for CDK7 and IRAK4 inhibitors

Objective responses seen with PARP inhibitor BGB-290 in patients with solid tumors

Adocia reports results of phase Ib trial of BioChaperone Combo in type 2 diabetes

New orally available PD-1 inhibitor shows positive antitumor activity

NHI price for Ryzodeg FlexTouch listed in Japan

Takeda Pharmaceutical discloses M1 modulators

Ariad Pharmaceuticals reports mutant tyrosine kinase inhibitors

Novartis patents SMURF1 inhibitors

Roche and PTC Therapeutics introduce SMN2 splicing modulators

Shionogi presents anti-HIV agents

Bayer Schering Pharma divulges sGC activators

Sinclair IS Pharma to divest non-esthetics business to Alliance Pharma

ReproCELL acquires Biopta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 25, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026